Clay Siegall Promises A Brighter Future Through Better Cancer

Home / Clay Siegall Promises A Brighter Future Through Better Cancer


Getting good results after looking to find a solution to a health challenge like cancer takes the effort of experts in various specialties. Clay Siegall is among experts who have invested a lot to developing better cancer research methods. His idea is to come up with solutions that will put to an end the worry about cancer by developing reliable and strong cancer treatment methods. Although this is a field that has been around for many years, cancer research is yet to develop a fully reliable solution for the treatment of the disease.

Many companies and institutes have also chipped in to also do their part in the fight against cancer. Seattle Genetics, founded by Clay Siegall, has been key in delivering solutions that are developed with a focus on eliminating cancer. In a recent release, the company unveiled a new technology, the ADC Technology, which is quite promising and developed to offer an easier way of dealing with cancer. Through this technology, the cancer treatment process is made easier by the fact that it targets cancerous cells and kills them while sparing all healthy cells. This is unlike the popular methods that have been in use over the years since none could guarantee such a process. Several companies joined Seattle Genetics to support this revolutionary technology.

About Clay Siegall

Clay Siegall is a renowned scientist, who is the CEO and founder of a highly developed biotechnology company, Seattle Genetics. He supports research to develop highly effective and reliable cancer treatment methods and his company has helped in this space by producing the ADC Technology that makes treating cancer easier. He has also been working with the executives of other companies to chart ways forward and enter into strategic licenses that would allow joint effort in the fight to get a reliable cancer treatment method.

Between 1988 and 1991, Clay Siegall worked with the National Institute of Health and the National Cancer Institute. In 1991, he joined the Bristol-Meyers Squibb Pharmaceutical Institute, where he worked until 1997. In 1998, he founded Seattle Genetics and has been working as the CEO of the company.